Young, H., Baum, R., Cremerius, U., et al. (1999) Measurement of Clinical and Subclinical Tumor Response Using [18F]-Fluorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations. European Organization for Research and Treatment of Cancer (EORT C) PET Study Group. European Journal of Cancer, 35, 1773-1782.
https://doi.org/10.1016/S0959-8049(99)00229-4

has been cited by the following article:

• TITLE: Advances in the Treatment of Advanced Non-Small Cell Lung Cancer

  AUTHORS: Xianshan Chen, Juncheng Guo, Min Guo

  KEYWORDS: Non-Small Cell Lung Cancer, Drugs, Targeted, Chemotherapy

  JOURNAL NAME: Advances in Lung Cancer, Vol.9 No.2, June 29, 2020

  ABSTRACT: In recent years, the incidence of lung adenocarcinoma has been increasing, and now it has become the largest type of non-small cell lung cancer (NSCLC). Currently, treatment of advanced NSCLC consists of several modalities: systemic chemotherapy, local radiation therapy, and targeted therapy (including most recently immunotherapy). In the past decade, the discovery of new molecular subtypes, the search for tumor driver gene mutations, the development of targeted molecular targeted drugs, or targeted therapy to suppress tumor angiogenesis and regulate tumor immune response have been the main directions of NSCLC research and clinical diagnosis and treatment. At present, platinum-based chemotherapy is widely used in NSCLC patients clinically. Platinum-based chemotherapy drugs can effectively prolong the survival time of patients and improve their quality of life, but the incidence of adverse reactions is still high. Therefore, it is necessary to find a drug that can improve the efficacy of patients and reduce the adverse reactions of platinum chemotherapy drugs to NSCLC patients.